CHICAGO (Reuters) – Boston Scientific Corp suspended sales of its implantable heart defibrillators on Monday after failing to notify regulators of changes in how it manufactures the devices, sending shares down as much as 19 percent to a one-year low.


Continued here:
Boston Scientific suspends ICD sales, shares slump